Boston Scientific Lifts 2024 Outlook After Strong 1Q
By Dean Seal
Boston Scientific has raised its earnings and sales guidance for 2024 after logging a higher profit and stronger-than-expected revenue growth in the first three months of the year.
The Marlborough, Mass.-based biomedical engineering company is now guiding for sales to rise 11% to 13% this year, up from its previous target for 8.5% to 9.5% growth, and for earnings to hit $1.43 to $1.48 a share, compared with its prior outlook for $1.38 to $1.42 a share. Adjusted earnings, which strip out one-time items, are now expected to come in at $2.29 to $2.34 a share, up from its most recent guidance for $2.23 and $2.27 a share.
The raise comes after Boston Scientific posted a first-quarter profit of $495 million, or 33 cents a share, compared with $300 million, or 21 cents a share, in the same quarter a year ago.
Adjusted earnings were 56 cents a share. Analysts polled by FactSet had been expecting 51 cents a share, while the company had guided for 50 cents to 52 cents a share.
Revenue rose to $3.86 billion from $3.39 billion in the year-ago quarter, topping analyst projections for $3.68 billion, according to FactSet.
Sales in its MedSurg segment were up more than 10%, while the top line of its cardiovascular unit jumped nearly 16%.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 24, 2024 07:01 ET (11:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks